HUNT et al. v. MEZENTCO SOLUTIONS INC., et. al.
(Chemotherapy Dilution Dosing Incident Class Action)
The Class Members
You were a Class Member in this class action if you were one of the 1202 cancer patients, or their estates, who underwent chemotherapy treatment at Windsor Regional Hospital, London Health Sciences Centre, Lakeridge Health, Peterborough Regional Health Centre or the Regional Health Authority B (Saint John Regional Hospital) (“Hospitals”), between February 6, 2012 and April 2, 2013 (“Class Period”). You were a Family Class Member if you were a living partner, spouse, child, grandchild, parent, grandparent or sibling of a Class Member.
The Class Action
The Class Action lawsuit alleged that the negligence of Mezentco Solutions Inc., c.o.b. Marchese Hospital Solutions, Mezentco Inc., c.o.b. Marchese Health Care and MedBuy Corporation (collectively, the “Defendants”) caused Class Members to receive lower than intended dosages of the chemotherapy drugs cyclophosphamide and/or gemcitabine (the “Dosing Incident”).
The Plaintiffs entered into a proposed Settlement Agreement with the Defendants and Hospitals. This Settlement required court approval before it became effective. A copy of the Settlement Agreement may be downloaded from the Documents page of this website.
On April 7, 2017, the Honourable Justice Verbeem of the Ontario Superior Court of Justice, approved the Settlement of this class action and appointed Marsh Risk Consulting Canada (“Marsh”) as Settlement Administrator.